NGF Antibody Fasinumab Currently in Phase 2/3 Osteoarthritis Trial   Tarrytown, N.Y., Oct. 1, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration with Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (MTPC) providing MTPC with exclusive development and commercial rights to fasinumab (REGN475), Regeneron’s NGF antibody in late-stage development for musculoskeletal pain. Under […]